Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Managing hematological cancer patients during the COVID-19 pandemic: an ESMO-EHA Interdisciplinary Expert Consensus
Christian Buske, Martin Dreyling, Alberto Álvarez‐Larrán, et al.
ESMO Open (2022) Vol. 7, Iss. 2, pp. 100403-100403
Open Access | Times Cited: 51

Showing 1-25 of 51 citing articles:

Myelofibrosis
Francesco Passamonti, Barbara Mora
Blood (2022) Vol. 141, Iss. 16, pp. 1954-1970
Open Access | Times Cited: 64
COVID-19 in patients with anemia and haematological malignancies: risk factors, clinical guidelines, and emerging therapeutic approaches
Sareh Kakavandi, Bahareh Hajikhani, Paniz Azizi, et al.
Cell Communication and Signaling (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 7
COVID-19 and Other Underlying Causes of Cancer Deaths — United States, January 2018–July 2022
S. Jane Henley, Nicole F. Dowling, Farida B. Ahmad, et al.
MMWR Morbidity and Mortality Weekly Report (2022) Vol. 71, Iss. 50, pp. 1583-1588
Open Access | Times Cited: 35
Association between allergic conditions and COVID-19 susceptibility and outcomes
Chao Chen, Xue Song, Dana J. Murdock, et al.
Annals of Allergy Asthma & Immunology (2024) Vol. 132, Iss. 5, pp. 637-645.e7
Open Access | Times Cited: 6
Guía para el diagnóstico y el tratamiento de la leucemia linfocítica crónica y el linfoma linfocítico de células pequeñas del Grupo Español de Leucemia Linfocítica Crónica (GELLC)
Ángeles Medina, Ana Muntañola, Marta Crespo, et al.
Medicina Clínica (2025)
Closed Access
Exploration of risk factors and characteristics of COVID-19 infection among patients with hematological malignancies in Suzhou, China: a retrospective study
Yao Yao, Wenjuan Di, Fangkai He, et al.
Frontiers in Oncology (2025) Vol. 14
Open Access
Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia and small lymphocytic lymphoma from Chronic Lymphocytic Leukemia Spanish Group (GELLC)
Ángeles Medina, Ana Muntañola, Marta Crespo, et al.
Medicina Clínica (English Edition) (2025)
Closed Access
Management of patients with lymphoma and COVID‐19: Narrative review and evidence‐based practical recommendations
Francesco Passamonti, Emanuele Nicastri, Alice Di Rocco, et al.
Hematological Oncology (2022) Vol. 41, Iss. 1, pp. 3-15
Open Access | Times Cited: 18
Evidence-based expert consensus on clinical management of safety of Bruton's tyrosine kinase inhibitors (2024).
Zaiwei Song, Dan Jiang, Lingling Yu, et al.
PubMed (2024) Vol. 36, Iss. 3, pp. 240-256
Closed Access | Times Cited: 3
Uptake of COVID-19 vaccination in people with blood cancer: Population-level cohort study of 12 million patients in England
Jennifer Hirst, Emma Mi, Emma Copland, et al.
European Journal of Cancer (2023) Vol. 183, pp. 162-170
Open Access | Times Cited: 8
Charting a path forward: Promising outcomes of convalescent plasma therapy in the care of severely B‐cell depleted patients with persistent COVID‐19
Tsofia Inbar, Eldad J. Dann, Omer Kerner, et al.
Transfusion (2024) Vol. 64, Iss. 3, pp. 443-448
Closed Access | Times Cited: 2
IELSG38: phase II trial of front-line chlorambucil plus subcutaneous rituximab induction and maintenance in mucosa-associated lymphoid tissue lymphoma
Anastasios Stathis, Maria Cristina Pirosa, Lorella Orsucci, et al.
Haematologica (2024)
Open Access | Times Cited: 2
Management of vaccinations in patients with non‐Hodgkin lymphoma
Michele Merli, Andrea Costantini, Silvio Tafuri, et al.
British Journal of Haematology (2024) Vol. 204, Iss. 5, pp. 1617-1634
Open Access | Times Cited: 2
Amyloidosis and COVID-19: experience from an amyloid program in Canada
Ellen M. Lewis, Nowell M. Fine, Robert J.H. Miller, et al.
Annals of Hematology (2022) Vol. 101, Iss. 10, pp. 2307-2315
Open Access | Times Cited: 13
SARS‐CoV‐2 infection in patients with chronic lymphocytic leukemia: The Italian Hematology Alliance on COVID‐19 cohort
Michele Merli, Isacco Ferrarini, Francesco Merli, et al.
Hematological Oncology (2022) Vol. 41, Iss. 1, pp. 128-138
Open Access | Times Cited: 12
COVID-19 Vaccination Response and Its Practical Application in Patients With Chronic Lymphocytic Leukemia
Mazyar Shadman, Catherine Liu, Katherine Eakle, et al.
HemaSphere (2022) Vol. 7, Iss. 1, pp. e811-e811
Open Access | Times Cited: 12
Delays in diagnosis and surgery of sarcoma patients during the COVID-19 outbreak in Spain
Jaime Carrillo, Serena Lacerenza, Nadia Hindi, et al.
Therapeutic Advances in Medical Oncology (2024) Vol. 16
Open Access | Times Cited: 1
Waldenstrom Macroglobulinemia
Michele Bibas
Elsevier eBooks (2024), pp. 270-308
Closed Access | Times Cited: 1
Leveraging G-CSF prescribing in the outpatient setting: considerations beyond clinical factors—a questionnaire study
Florian Scotté, Pascal Artru, Mahasti Saghatchian, et al.
Supportive Care in Cancer (2024) Vol. 32, Iss. 6
Closed Access | Times Cited: 1
Early impact of treatment modifications adopted for acute lymphoblastic leukemia during SARS-CoV-2 pandemic; a single center experience and lessons for LMICs
Esraa Maged Mohammad, Moatasem El‐Ayadi, Ahmad Kamel, et al.
Leukemia & lymphoma/Leukemia and lymphoma (2024), pp. 1-7
Closed Access | Times Cited: 1
Risk of COVID-19 infection in patients with NSCLC receiving EGFR-TKI targeted therapy during the first wave in China
Peng Huang, Ling-Ming Liao, Jiali Zhao, et al.
Journal of International Medical Research (2024) Vol. 52, Iss. 10
Open Access | Times Cited: 1
Quantitative Analysis of SARS-CoV-2 Antibody Levels in Cancer Patients Post Three Doses of Immunization and Prior to Breakthrough COVID-19 Infections
Kathryn Macrae, Jorge Martínez-Cajas, Kristin Bessai, et al.
Current Oncology (2022) Vol. 29, Iss. 10, pp. 7059-7071
Open Access | Times Cited: 8
Follicular lymphoma: an update on biology and optimal therapy
Luca Fischer, Martin Dreyling
Leukemia & lymphoma/Leukemia and lymphoma (2023) Vol. 64, Iss. 4, pp. 761-775
Closed Access | Times Cited: 3
Tixagevimab/Cilgavimab as Pre-Exposure Prophylaxis against COVID-19 for Multiple Myeloma Patients: A Prospective Study in the Omicron Era
Ioannis Ntanasis‐Stathopoulos, Charalampos Filippatos, Maria Gavriatopoulou, et al.
Diseases (2023) Vol. 11, Iss. 3, pp. 123-123
Open Access | Times Cited: 3
Indolent lymphoma care delivery and outcomes during the COVID‐19 pandemic in Ontario, Canada
Inna Y. Gong, Anca Prica, Zharmaine Ante, et al.
British Journal of Haematology (2023) Vol. 204, Iss. 3, pp. 805-814
Closed Access | Times Cited: 3
Page 1 - Next Page

Scroll to top